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Cotrimoxazole for childhood febrile illness in 
Malaria-endemic regions 
PB Bloland, SC Redd, PN Kazembe, R Tembenu,jJ Wirima, CC Campbell 
The efficacy of co-trimoxozole for the treatment 
of Plasmodium falcipanlm parasitaemia in child-
ren younger than 5 years of age was evaluated in 
Malawi. 46 children with P falcipanlm parasitae-
mia, 37% of whom also met clinical criteria for a 
diagnosis of acute lower respiratory tract infec-
tion, were treated with 20 mglkg co-trimoxazole 
twiee daily for five days. Parasitaemia (mean clea~ 
anee time 2.7 days) and symptoms were rapidly 
abolished and improvement was maintained d~ 
ing follow-up for 14 days. Co-trimoxazole may be 
an effective single treatment for febrile illness in 
young children in areas where malaria is endemic, 
resources are few, and diagnosis must rely on 
clinical findings alone. 
Two of the commonest causes of childhood mor-
tality in sub-Saharan Mrica are malaria and acute 
lower respiratory wct infection (ALRI), Because of 
limitations in diagnostic technology and personnel, 
disease-specific clinical case definitions have been 
devised to standardise treatment for these and 
other major causes ,~;childhood illness~ The case 
definition for malaria, when microscopy is unavail-
able, is based on the presence or history of fever 
without other obvious cause. In practice, the World 
Health Organisation (WHO) recommends that in 
highly endemic areas all young children with fever 
should be treated for malaria, because of the likeli-
hood of malaria infection as a complicating factor. 
The case definition for ALRI is cough or a history 
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of cough and an increase in respiratory .ate (rate 
of or above 60 breaths/min for children under 2 
months of age, 50 breaths/min for children 2-12 
months old, and 40 breaths/min for children over 
12 months of age), But the poor specificity of these 
definitions may lead to multiple diagnoses and 
multiple therapies. 
The World Health Organisation at present rec-
ommends that children who meet case definitions 
for both malaria and ALRI should receive both 
antibacterial and antimalarial drugs. Co-trimoxa-
zole, the combination of trimethoprim and sulpha-
methoxazole, is recommended for the treatment of 
childhood ALRI, it affects the same enzymes as the 
combination of pyrimethamine and sulfadoxine, 
used for treatment of chloroquine-resistant Plasmo-
dium falcipanlm infections. Co-trimoxazole is 
known to bean effective treatment of P falciparum 
in children older than 5 years and in adults, with 
cure rates above 98%. We set out to assess the 
efficacy of co-trimoxazole for the treatment of P 
falciparum in children under 5 years of age, who 
might h;l.ve less immunity t~ P falciparum, in an Clfe;l 
ef intense chloroquine resistance. . 
Children under 5 years of age with complaints 
of fever, cough or dyspnoea were selected from 
patients brought to the outpatient clinic of the 
largest hospital in Lilongwe, Malawi, during the two 
months of highest malaria transmission. Mter a 
standard clinical examination thick blood-smears 
were examined for P falciparum infection; parasite 
density was estimated by standard methods. Child-
ren were screened for previous anti malaria drug 
use with the Saker-Solomon urine test for 4-amino-
quinolines. Chest radiographs were assessed by a 
paediatric radiologist unaware of the clinical de-
tails. 
Children entered into the study were non-ran-
domly selected from the screened children if they 
met the following criteria age between 3 months 
and 5 years, confinued pure P falciparum infection 
of at least 2000 asexual parasites/ ml, and informed 
parental consent. Children who required hospital 
admission were excluded. Initially, only children 
with negative urine tests for previous chloroquine 











































Children were treated with co-trimoxazole at a 
dosage of 20 mg/kg (based on sulphamethoxazole) 
twice daily for 5 days, the recommended treatment 
regimen for childhood ALRI; each dose was admin-
istered by a member of the study team. Follow-up 
consisted of a clinical examination on each day of 
treatment and on days 7 and 14, with blood smears, 
respiratory rates, and haemoglobin concentrations 
obtained on each assessment day. Axillar)' tempera-
tures and history of fever, vomiting, diarrhoea, 
cough, rash, or other adverse reactions to treat-
ment were obtained twice daily during treatment 
and on days 7 and 14. 
Response to therapy was assessed by three 
criteria: parasite clearance, fever clearance, and 
resolution of clinical symptoms. Parasite clearance 
was defined as the time between the start of treat-
ment and the first of two consecutive negative 
blood smears. Fever clearance was defined as the 
time between the start of treatment and the 
first of two consecutive normal axillary tempera-
tures (below 37.5°C) in children who were initially 
febrile. Children were considered to have clinically 
responded if they no longer met the case de-
finitions for either malaria or ALRI and were 
judged to be active and well by the mother or 
guardian. 
Of 1605 children examined during the initial 
screening process, 979 (61%) met the malaria case 
definition alone, 449 (28%) met both malaria and 
ALRI definitions, and 32 (2%) met the ALRI defini-
tion alone, 46 children were entered into the co-tri-
moxazole study. 2 moved out of the study area after 
day 7, so 44 (95%) children were followed to day 
14. The median age was 18 months (range 3.5-52.6) 
and 26 (56.5%) were girls. The geometric mean 
parasite density on enrolment was 21807 asexual 
parasites/ml (range 2747-113212).40 (86.9%) had 
negative Saker-Solomon urine tests; the response 
to co-trimoxazole of those with positive urine tests 
did not differ from those with negative tests, so the 
results have been merged. 
20 children initially complained offever without 
cough, 7 of cough without fever, and 19 of both 
fever and cough. 33 (71.7%) were febrile when 
brought to the clinic, with a mean temperature of 
38.3°C (range 36.0-40.7); mean fever clearance time 
was 1.5 days. 17 (37.0%) children met the ALRI case 
definition (15 of whom were also febrile), and 5 
(10.9%) had radiographic evidence of pneumonia. 
Of the 17 children who met the ALRI case defini-
tion, 14 (82.4%) no longer met the definition by day 
14. Children who did and who did not meet the 
ALRI case definition had similar mean parasite 
clearance times (2.6 and 2.8 days, respectively; 
p=O.5), but children who met the ALRI case 
definition had a longer mean fever clearance 
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time than those who did not (1.9 days and 1.1. days, 
respectively; p=O.OI). Children with radiographic 
evidence of pneumonia had a mean parasite clear-
ance of 2.2 days and a mean fever clearance of 1.0 
day. Parasitaemia was abolished in all 44 children 
followed up for 14 days, with a mean parasite 
clearance time of2.7 days (range 1-5). All but one 
child remained parasite-free to day 14; the excep-
tion had a blood smear with 300 asexual para-
sites/ml on day 14, but blood smears were negative 
on days 15, 16, 19 and 21 without additional treat-
ment. 
The study population illustrates the difficulties 
that may arise from strict application of case defini-
tions for malaria and ALRI. 28% of patients en-
tered into the initial screening process met the 
definition for both malaria and ALRI and would 
thus have been considered for multiple therapy. 
Similarly, of the 46 children with parasitaemia en-
tered into the co-trimoxazole study, 17 (37%)also 
met the ALRI case definition, 5(10.9%) of whom 
had radiographic evidence of pneumonia. Co-tri-
moxazole effectively and rapidly cleared P Jalcipa-
rum parasitaemia and clinical symptoms in these 
young Malawian children. Because of its lengthy 
dosage regimen, co-trimoxazole is a poor drug for 
the treatment of malaria alone and its use is limited 
to areas where P Jalciparum remains sensitive to 
folate antagonists. Nevertheless, use of co-trimoxa-
zole alone represents an effective treatment. f6r 
young children in areas where the childrerf""with 
ALRI alone cannot reliably be distinguished from 
those with both ALRI and malaria. 
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